Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

Delayed Quote. Delayed  - 06/29 09:59:19 pm
1.34 USD   +0.75%
06/22 Pluristem Reports Data Showing PLX-PAD Cells Effective in Treatin..
05/20 PLURISTEM THERA : Completes Enrollment of 150 Patients in Phase II I..
05/17 PLURISTEM THERA : Completes Enrollment of 150 Patients in Phase II I..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/23/2016 06/24/2016 06/27/2016 06/28/2016 06/29/2016 Date
1.36(c) 1.29(c) 1.28(c) 1.33(c) 1.34 Last
165 363 118 303 82 271 90 842 63 067 Volume
+0.74% -5.15% -0.78% +3.91% +0.75% Change
More quotes
Financials ($)
Sales 2016 2,85 M
EBIT 2016 -24,7 M
Net income 2016 -23,7 M
Debt 2016 -
Yield 2016 -
Sales 2017 1,21 M
EBIT 2017 -29,9 M
Net income 2017 -26,6 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 37,4x
Capi. / Sales2017 88,3x
Capitalization 107 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : - Investor Rating :
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
06/22 Pluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne M..
05/31 PLURISTEM THERAPEUTICS INC : Change in Directors or Principal Officers, Submissi..
05/20 PLURISTEM THERAPEUTICS : Completes Enrollment of 150 Patients in Phase II Interm..
05/17 PLURISTEM THERAPEUTICS : Completes Enrollment of 150 Patients in Phase II Interm..
05/16 PLURISTEM THERAPEUTICS : Completes Enrollment of 150 Patients in Phase II Interm..
05/10 PLURISTEM THERAPEUTICS : Reports Third Quarter Fiscal 2016 Financial Highlights ..
05/09 BRIEF : Israeli stem cell co Pluristem receives $3.3m grant
05/09 Pluristem Awarded $3.3 Million Grant by Israeli Government
04/22 PLURISTEM THERAPEUTICS : Enters Into Licensing Agreement with TES Holdings Co., ..
04/21 Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a vent..
More news
Sector news : Biotechnology & Medical Research - NEC
06/28DJGILEAD SCIENCES : Gets FDA Approval for Combo Hepatitis C Drug
06/28DJGILEAD SCIENCES : Gets FDA Approval for Combo Hepatitis C Drug
06/28DJGILEAD SCIENCES : Gets FDA Approval for Combo Hepatitis C Drug
06/28 GILEAD SCIENCES : FDA approves first pill to treat all forms of hepatitis C
06/28 MAKING AN IMPACT AROUND THE GLOBE : Amgen Czech Republic Staff Give Back to Thei..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/22 Midday Gainers / Losers
06/22 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/22 PREMARKET GAINERS / LOSERS AS OF 9 : 15 am
06/22 Pluristem's PLX-PAD cells shows positive effect in animal model of muscular d..
06/03 Is It Time To Invest In Stem Cell Biotechs?
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions